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Abstract
Background: Treatment of Escherichia coli O157:H7 infections with antimicrobial agents is controversial due to an
association with potentially fatal sequelae. The production of Shiga toxins is believed to be central to the
pathogenesis of this organism. Therefore, decreasing the expression of these toxins prior to bacterial eradication
may provide a safer course of therapy.
Methods: The utility of decreasing Shiga toxin gene expression in E. coli O157:H7 with rifampicin prior to bacterial
eradication with gentamicin was evaluated in vitro using real-time reverse-transcription polymerase chain reaction.
Toxin release from treated bacterial cells was assayed for with reverse passive latex agglutination. The effect of this
treatment on the survival of E. coli O157:H7-infected BALB/c mice was also monitored.
Results: Transcription of Shiga toxin-encoding genes was considerably decreased as an effect of treating E. coli O157:
H7 in vitro with the minimum inhibitory concentration (MIC) of rifampicin followed by the minimum bactericidal
concentration (MBC) of gentamicin (> 99% decrease) compared to treatment with gentamicin alone (50-75% decrease).
The release of Shiga toxins from E. coli O157:H7 incubated with the MIC of rifampicin followed by addition of the MBC
of gentamicin was decreased as well. On the other hand, the highest survival rate in BALB/c mice infected with E. coli
O157:H7 was observed in those treated with the in vivo MIC equivalent dose of rifampicin followed by the in vivo MBC
equivalent dose of gentamicin compared to mice treated with gentamicin or rifampicin alone.
Conclusions: The use of non-lethal expression-inhibitory doses of antimicrobial agents prior to bactericidal ones in
treating E. coli O157:H7 infection is effective and may be potentially useful in human infections with this agent in
addition to other Shiga toxin producing E. coli strains.
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Background
Escherichia coli O157:H7 is the most commonly
encountered member of the Enterohemorrhagic Escheri-
chia coli (EHEC) group. Infection with this agent typi-
cally results in bloody diarrhea with low-grade or
absence of fever with no leukocytes in the stools [1].
Symptoms may progress, culminating in potentially fatal
complications such as the hemolytic uremic syndrome
(HUS) [2-4] and thrombotic thrombocytopenia purpura
(TTP) in the elderly and the young [3]. This organism
causes about 73,000 illnesses annually in the United
States [5].
Until recently, the most common mode of E. coli
O157:H7 infection was via the oral route by consump-
tion of ground beef. In recent years, E. coli O157:H7 has
been isolated with increasing frequency from fresh
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of animal products, person-to-person transmission,
waterborne, animal contact and less commonly, labora-
tory-associated transmission [6]. Several virulence factors
contribute to the pathogenicty of E. coli O157:H7 with
the production of Shiga toxins (Stxs) being at the epicen-
ter of the infectious process. These toxins consist of two
major groups: Stx1, which is nearly identical to the toxin
of Shigella dysenteriae type 1, and Stx2, which shares less
than 55% amino acid sequence with Stx1 [7-9]. Another
virulence factor is the locus of enterocyte effacement
(LEE) which contains genes required for the production
of the attaching and effacing (A/E) lesions that accom-
pany E. coli O157: H7 infection [10]. These genes basi-
cally allow the bacteria to colonize the intestines. The
Shiga toxins have also been implicated in contributing to
the process of intestinal colonization [11].
Treating E. coli O157:H7 infection with antimicrobial
agents is currently contraindicated due to its association
with HUS and an increased case-fatality rate [12-14]. This
m a yb ed u et ot h ea c t i v a t i o no fas t r e s sr e s p o n s es i g n a l
upon treatment with the antimicrobial agent that poten-
tially leads to enhanced production and subsequent release
of Shiga toxins [15]. Alternatively, the antimicrobial agent
may lead to bacterial lysis and subsequent release of stored
toxins that are present in the periplasmic space [16].
A potential method of treatment may involve adminis-
t r a t i o no fa na n t i m i c r o b i a lagent at non-bactericidal
doses that limit toxin expression prior to employing an
agent at bactericidal doses. This would decrease toxin
production prior to bacterial cell lysis and hence may cir-
cumvent the sequelae associated with this type of infec-
t i o n .W eh a v ep r e v i o u s l yd e m o n s t r a t e dt h a tm i n i m u m
inhibitory concentrations (MIC) of rifampicin effectively
decreased toxin release from E. coli O157:H7 in vitro
[17,18]. We have also shown that this agent improves the
survival rate of mice infected with E. coli O157:H7 [19].
Employment of rifampicin in monotherapy is associated
with evolution of rapid resistance [20]. Hence, we investi-
gated the utility treating infected mice with rifampicin at
doses that limit toxin expression followed by gentamicin
at bactericidal doses to eradicate the bacterial agent.
Methods
In vitro antimicrobial susceptibility testing
The minimum inhibitory concentration (MIC) and mini-
mum bactericidal concentration (MBC) of rifampicin
and gentamicin for the CDC 26-98 strain E. coli O157:
H7 were determined as previously described [19].
Real-time reverse-transcription polymerase chain reaction
(RT-PCR) for assessing toxin gene transcription
To assess the effect of treating E. coli O157:H7 cells
with rifampicin and gentamicin on toxin gene
expression multiple regimens were tested. An inoculum
of 10
6 CFU of the CDC 26-98 strain of E. coli O157:H7
in 2 ml of Mueller Hinton broth was incubated in the
MIC of rifampicin for 18 hrs at 37°C. A similar inocu-
lum was incubated in the MBC of gentamicin for 18 hrs
at 37°C. A different sample was incubated in the MIC of
rifampicin for 18 hrs at 37°C, cells were then centrifuged
(5000 rpm, 5 min), and resuspended in the MBC of gen-
tamicin prior to incubation for 4 hrs at 37°C. Similarly a
sample was incubated in the MIC of rifampicin for 18
hrs at 37°C. Cells were then centrifuged and resus-
pended in the MBC of rifampicin prior to further incu-
bation for 4 hrs at 37°C. An inoculum of E. coli O157:
H7 grown in 2 ml of antimicrobial agent-free broth for
22 hrs at 37°C was also included as a normal growth
control. None of the samples incubated with the antimi-
crobial agents showed any growth.
After incubations, total RNA was extracted from 10
6
CFU of each of the samples described above using the
Illustra RNAspin Mini RNA Isolation Kit (General Elec-
tric Company, United Kingdom) according to the manu-
facturer’s specifications for bacterial cells. Reverse
transcription and cDNA synthesis was then performed
on all samples of extracted RNA using the QuantiTect
®
Reverse Transcription Kit (QIAGEN, Germany) accord-
ing to the manufacturer’s instructions. Gene expression
was then assessed with real-time PCR for the stx1 and
stx2 genes, that respectively encode Shiga toxin 1 (Stx1)
and Shiga toxin 2 (Stx2). This was performed using a
BioRad CFX96 Real Time System, C1000 Thermal
Cycler (Germany). Primers were obtained from Thermo
Scientific (Ulm, Germany). Previously published primers
were used for detection of stx1 and stx2 transcripts [21].
Reactions (20 μl), performed in triplicates per sample,
each contained 738 ng cDNA, 10 pmoles of each primer
and 1 × QuantiFast SYBR green PCR mix (Qiagen, ger-
many). Reactions were incubated at 95°C for 15 minutes
followed by 45 cycles of 95°C for 10 seconds, 55°C for
10 seconds and 72°C for 20 seconds.
Relative expression (RE) was calculated using the for-
mula: RE = (1+ % E)
ΔCt, where E is the efficiency of the
real-time run and ΔCt is the difference between the Ct
value of samples extracted from E. coli O157: H7 grown
in the absence of drugs and the Ct value of the antimi-
crobial agent-treated samples. In our experiments, we
used an efficiency value of 100%, therefore, the equation
employed for the analysis was: RE = (1 + 1)
ΔCt =( 2 )
ΔCt. Expression levels were normalized to those detected
in bacterial samples incubated with drug-free media.
Reverse passive latex agglutination (RPLA) for assessing
toxin release
VTEC-RPLA “SEIKEN” kit (Denka Seiken, LTD., Tokyo,
Japan) was used to assess Stx1 and Stx2 release from
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MBC of gentamicin. E. coli O157:H7 was grown for 18
hrs at 37°C in rifampcin-containing TSB followed by
additional 4 hrs of incubation with the MBC of gentami-
cin. Toxin titers were then determined by reverse pas-
sive latex agglutination (RPLA) and compared to E. coli
O157:H7 grown in antimicrobial free TSB. When toxin
titers were tested in bacterial cultures grown in the MIC
or MBC of rifampicin, growth inhibition was accounted
for and CFU numbers were adjusted to be equivalent to
those grown in antimicrobial agent-free media.
Antimicrobial treatment of E. coli O157:H7-infected BALB/
c mice
Adult male BALB/c mice, 4-6 weeks old and weighing
22-39 g each, were obtained from the Animal Care
Facility at the American University of Beirut (AUB). The
LD50 of the CDC 26-98 strain of E. coli O157:H7 in
these mice was determined as previously described [19].
To assess the utility of an antimicrobial regimen for the
treatment of infected mice, seven groups each contain-
ing 8 mice were used (Table 1). Mice received 3 × LD50
of the CDC 26-98 strain of E. coli O157:H7 and then
were treated with the in vivo MIC equivalent dose of of
rifampicin (15.168 μg), the in vivo MBC equivalent dose
of gentamicin (7.584 μg) or with both successively. A
group that was treated with the in vivo MIC equivalent
dose of rifampicin followed by the MBC equivalent dose
of the same agent was also assessed. Groups of mice
that were not infected but injected with sterile broth or
with the antimicrobial agents in addition to a group that
was infected but not treated were included as controls.
All injections were administered intraperitoneally and
their volumes did not exceed 0.5 ml/mouse/day. Mice
were then monitored for death and weight change over
a period of 14 days. Mice were to be euthanized had
they lost more than 30% of their body weight post-
infection; however, this did not occur during the 14 day
monitoring period.
The therapeutically relevant in vivo MIC equivalent
dose of rifampicin was extrapolated from its in vitro
MIC according to the following formula: rifampicin in
vivo MIC dose (μg) = [rifampicin in vitro MIC (μg/μl) ×
in vitro MIC broth volume (μl) × E. coli O157:H7 CFU
administered in vivo]/E. coli O157:H7 CFU per in vitro
MIC reaction. Consequently, the ratio of rifampicin to
E. coli O157:H7 CFU determined by in vitro MIC test-
ing was maintained in vivo. Similarly, the therapeutically
relevant in vivo MBC equivalent dose of rifampicin was
extrapolated from its in vitro MBC according to the fol-
lowing formula: rifampicin in vivo MBC dose (μg) =
[rifampicin in vitro MBC (μg/μl) × in vitro MBC broth
volume (μl) × E. coli O157:H7 CFU administered in
vivo]/E. coli O157:H7 CFU per in vitro MBC reaction.
The same formula was used to determine the in vivo
MBC equivalent dose of gentamicin.
Results
Effect of in vitro treatment with antimicrobial agents on
toxin expression in E. coli O157:H7
Multiple rifampicin and gentamicin treatment regimens
were used to assess the effect of these agents on the
expression of Stx1 and Stx2 encoding genes, stx1 and stx2,
in E. coli O157:H7. Treatments tested are described in the
materials and methods section. Real-time RT-PCR showed
that the stx1 and stx2 genes were expressed in the E. coli
O157:H7 strain employed when incubated in antimicrobial
agent-free broth (Figure 1). After incubation with antimi-
crobial agents, levels of stx1 gene expression markedly
decreased (> 99% decrease) in the sample treated with the
MIC of rifampicin (8 μg/ml). A similar decrease was
observed in the sample treated with the MIC of rifampicin
followed by the MBC of rifampicin (16 μg/ml) and in the
sample treated with the MIC of rifampicin followed by the
MBC of gentamicin (4 μg/ml). The least inhibition of
toxin gene expression (51.37% decrease) was seen in the
sample treated with the MBC of gentamicin. A marked
decrease in stx2 transcript detection was observed in the
sample treated with the MBC of gentamcin (77%
decrease.) On the other hand, stx2 expression was comple-
tely inhibited by treatment with the MIC of rifmapicin,
treatment with the MIC of rifampicin followed by the
MBC of rifampicin, and treatment with the MIC of rifam-
picin followed by the MBC of gentamicin.
Treatment of E. coli O157:H7 with the MIC of rifam-
picin followed by the MBC of gentamicin showed an 8-
fold decrease of Stx1 toxin release into the growth med-
ium. On the other hand, there was no change in the
level of Stx2 released into the growth medium as com-
pared to toxin titers of E. coli O157:H7 grown in antimi-
crobial free broth (data not shown.)
Table 1 Mouse treatment regimen
Group First Injection
(Hour 0)
Second Injection
(Hour 1)
Third Injection
(Hour 17)
1 E. coli O157:H7
(3 × LD50)
Rifampicin (MIC) -
2 E. coli O157:H7
(3 × LD50)
Gentamicin (MBC) -
3 E. coli O157:H7
(3 × LD50)
Rifampicin (MIC) Gentamicin (MBC)
4 E. coli O157:H7
(3 × LD50)
Rifampicin (MIC) Rifampicin (MBC)
5 Trypticase soy broth Trypticase soy broth Trypticase soy broth
6 Trypticase soy broth Rifampicin (MIC) Gentamicin (MBC)
7 E. coli O157:H7
(3 × LD50)
--
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Page 3 of 7Figure 1 Relative transcription levels of the stx1 and stx2 genes in E. coli O157:H7 treated with antimicrobial agents. Bacterial inocula
were either grown in antimicrobial-agent free broth, treated with the minimal inhibitory concentration (MIC) of rifampicin or with the minimal
bactericidal concentration (MBC) of gentamicin. One sample was treated with the MIC of rifampicin followed by the MBC of rifampicin itself
while another was treated with the MIC of rifampicin followed by the MBC of gentamicin. RNA was then extracted from these samples.
Subsequently, the relative transcription levels of the stx1 and stx2 genes were assessed with real-time RT-PCR as described in the materials and
methods section. All expression levels were normalized to those detected in bacteria grown in antimicrobial agent-free broth. (A) Relative
transcription levels of the stx1 gene. (B) Relative transcription levels of the stx2 gene.
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infected mice
We have previously shown that treatment with the MIC
of rifamipicin was capable of significantly decreasing the
expression and release of both Stx1 and Stx2 from E.
coli O157:H7 [17-19]. This may be employed in a treat-
ment regimen whereby toxin production is limited prior
to administering an antimicrobial agent that can effec-
tively kill the bacteria. Therefore, we assessed this treat-
ment approach in vivo.
Mice were infected with 3 × LD50 of E. coli O157:H7
(equivalent to 9.48 × 10
5 CFU) and treated with various
regimens of rifampicin and gentamicin as summarized
in Table 1 and described in the materials and methods
section. All mice infected with E. coli O157:H7 and left
untreated or treated with the in vivo MBC equivalent
dose of gentamicin were dead by day 4 post infection
(Figure 2). Mice in other groups that survived until day
5 remained alive for the rest of the 14 day monitoring
period. The highest survival rate was obtained with the
group treated with the in vivo MIC equivalent dose of
rifampicin followed by the in vivo MBC equivalent dose
of gentamicin. In this group, 50% of the mice infected
and treated were alive on day 5 and remained so for-
ward. In comparison, 25% of the mice infected and trea-
ted with the in vivo MIC equivalent dose of rifampicin
w e r ea l i v eo nd a y5 .O nt h eo t h e rh a n d ,m i c et r e a t e d
post-infection with the in vivo MIC equivalent dose of
rifampicin followed by the in vivo MBC equivalent dose
of rifampicin showed a 12.5% survival rate.
Discussion
Using antimicrobial agents to treat E. coli O157:H7
infections has been contraindicated due to studies
showing an association between antimicrobial treatment
and increased fatality rates [4]. The quest for other
treatments has led to the development of antibodies,
among other agents, aimed at direct inhibition of the
toxins secreted by E. coli O157:H7 and associated with
the severe sequelae of infection [22,23]. While these
approaches appear to be effective, their affordability lim-
its their use. On the other hand, the use of probiotics,
physical means in addition to natural and chemical pro-
ducts for the treatment and prevention of E. coli O157:
H7 has been assessed by multiple groups with variable
success [24-28].
Antimicrobial agents remain to be the method of
choice for early empirical treatment of bacterial infec-
tions, particularly in the treatment of gastroenteritis in
pediatric patients [26]. Antimicrobial treatment for E.
coli O157:H7 may be possible if Shiga toxin expression
can first be decreased before administering bactericidal
doses of an agent, thus limiting potential toxin release
upon lysis of the organism. This was previously estab-
lished by our group in vitro [17,18] and by the study at
hand in vivo.
Upon establishing that in vitro treatment of E. coli
O157:H7 inocula with the MIC of rifampicin followed
by the MBC of gentamicin potently decreases the tran-
s c r i p t i o no ft h eS t x 1a n dS t x 2e n c o d i n gg e n e s ,w e
assessed the effect of this treatment mode on toxin
release. Testing the levels of toxins released into the
growth medium showed an 8-fold decrease in Stx2
levels whereas no such decrease was observed for Stx1
levels. This may be explained by the biology of produc-
tion and storage of these toxins and their turnover rates.
Stx1 is stored in the periplasmic space; consequently,
upon addition of gentamicin at a bactericidal
Figure 2 Number of surviving BALB/c mice after infection with E. coli O157:H7 and treatment with antimicrobial agents. Male BALB/c
mice were infected with E. coli O157:H7 and then treated with rifampicin and/or gentamicin as delineated in the materials and methods
section. Mice were then monitored for 14 days.
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pre-stored Stx1. On the other hand, Stx2 is typically
found in the extracellular fraction and is released from
bacterial cells [29].
Treatment of infected mice with the in vivo MIC
equivalent dose of rifampicin, followed by the in vivo
MBC equivalent dose of gentamicin increased the survi-
v a lr a t eo fi n f e c t e dm i c eb y5 0 % .O nt h eo t h e rh a n d
treatment with MBC equivalent dose of gentamicin led
to the death of all mice that received this agent. Rifam-
picin, being a known inhibitor of gene transcription, is
assumed here to have hindered the expression of the
toxins by E. coli O157:H7. After suppression of toxin
expression with rifampicin, treatment with gentamicin
helped eradicate the infection and enhance mouse
survival.
In a previous report [18], a higher fold-decrease in
toxin-release was seen in vitro when E. coli O157:H7
was incubated with rifampicin or gentamicin alone com-
pared to the decrease observed in the present study
upon combinatorial treatment. However, treatment of
infected mice with rifampicin followed by gentamicin
proved to be more effective than when these antimicro-
bial agents were used individually. Therefore, in vivo,
these antimicrobial agents may have had other effects
additional to affecting toxin expression and release.
These agents, for example, may have had a direct inhibi-
tory effect on the bacterial lipopolysacchride conse-
quently leading to decreased inflammation and septic
shock [30].
In addition, the combinational treatment of rifampicin
and gentamicin in vivo proved to be more effective than
treating with rifampicin alone, that is, treating the
infected mice with an MIC dose of rifampicin first, fol-
lowed later on by a bactericidal dose of the same drug.
A potential reason behind this is a resistance to rifampi-
cin that may have developed, and thus resulted in the
ineffective outcome of using an MBC dose of rifampicin,
as compared to that of gentamicin. Resistance to rifam-
picin by E. coli was reported shortly after rifampicin was
discovered. Susceptible bacteria, like E. coli, develop
resistance to rifampicin by one-step mutations that alter
the subunit structure of the RNA-polymerase, and this
takes place rapidly when rifampicin is used alone
[20,31].
Conclusions
The present study indicates that treatment with
rifampicin followed by gentamicin is capable of
decreasing toxin expression in E. coli O157:H7 in
vitro and improving the survival of mice infected with
this organism. Further investigations should indicate
cases where such a treatment modality would be of
benefit. Antibacterial agents should therefore not be
kept out of perspective for the treatment of E. coli
O157:H7 among other Shiga toxin-producing organ-
isms. However, care should be given to the selection
of agents with the appropriate mechanism of action.
The effect of these agents on toxin gene expression
should be taken into account. Agents that limit toxin
production prior to eradicating the bacterial infection
a r ep r e f e r a b l e .T h i sm a yb ea c h i e v e db yc o m b i n a t i o n
antimicrobial therapy such as the one described
herein.
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